Key regulator that induces cancer-killing capacity in T cells under hypoxia is identified
Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes, or TILs, ineffective. Thus, finding ways to disarm that resistance and rejuvenate anti-cancer TILs so they can kill tumor cells is an important goal for cancer clinicians. …read more
